MedTrace Logo

Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in Children

NCT07675291 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2026-06-30

No results posted yet for this study

Summary

The objective of this study is to assess the efficacy and safety of rituximab combining with low-dose mycophenolate mofetil in the induction therapy of proliferative lupus nephritis in children.

Conditions

Interventions

DRUG

rituximab

Rituximab is given monthly (375m/m2；maximum 500mg) for 6 doses

DRUG

Mycophenolate Mofetil (MMF) Treatment

The dose of mycophenolate mofetil is 10 to 15mg/kg/d for 6 months.

DRUG

Cyclophosphamide

The therapy for cyclophosphamide is 750mg/m2（maximum 1000mg） every month for 6 doses.

DRUG

ACEI / ARB

ACEI/ARB is recommended as the basic therapy for lupus nephritis.

DRUG

Corticosteroid

Corticosteroid is recommended as the basic therapy for lupus nephritis.

DRUG

Hydroxychloroquine (HCQ)

Hydroxychloroquine is recommended as the basic therapy for lupus nephritis.

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2028-12-31
Completion
2028-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07675291 on ClinicalTrials.gov